INVESTIGADORES
SANCHEZ BRUNI Sergio Fabian
artículos
Título:
‘Effects of formulation concentration on intravenous pharmacokinetics, chirality and in vitro solubility of oxfendazole and its metabolites in sheep.’
Autor/es:
2. SÁNCHEZ BRUNI, S.F, JONES, D., SMALL, J.;. MCKELLAR
Revista:
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
Editorial:
WILEY-BLACKWELL PUBLISHING, INC
Referencias:
Año: 2005 vol. 28 p. 467 - 473
ISSN:
0140-7783
Resumen:
ABSTRACT   This study compared pharmacokinetic (PK) profiles in sheep dosed intravenously with three different concentrations of oxfendazole (OFZ).  An in vitro plasma OFZ dissolution study provided additional information on plasma saturation.  For the PK study, 18 adult, parasite-free, female Suffolk cross sheep, allocated into three groups (n=6), were treated intravenously, at a dose rate of 5mg/kg bodyweight, with aqueous solutions containing at 4, 8 or 16% OFZ.  Plasma drug concentrations were measured, for up to 72 hours post-treatment, by a validated high performance liquid chromatography (HPLC) method with UV detection.  OFZ and fenbendazole sulphone (FBZSO2) were the main metabolites detected in all three experimental groups. In animals given the 4% solution, OFZ depleted according to a biexponential concentration vs. time curve.  In contrast, those given 8 or 16% preparations produced atypical curves fitted by monoexponential equations. No statistically significant differences in area under concentration-time curves (AUC) were observed, but concentration-dependent differences in distribution and mean residence time (MRT) were evident.  Compared with 4% OFZ, animals treated with 8 and 16% formulations had slower half-lives of metabolite formation,and lower AUC’s, suggesting that OFZ sulphonation may have been modified.  In vitro there was evidence of plasma saturation and precipitation associated with 8 and 16% OFZ preparations.  It is concluded that differences in PK profiles, in vivo, may have been related to inadequate dissolution and/or tissue drug precipitation.